Subscribe
Subscribe

V-Bio Ventures launches its second fund at EUR 78 million

First Closing of V-Bio Fund 2 is announced at EUR 78 million. V-Bio Fund 2 will ensure seamless continuation of investment activities in early-stage European life sciences companies. V-Bio Ventures announces expansion of executive team, with Shelley Margetson joining as Managing Partner

DoseVue obtains CE Mark for its first in-vivo dosimetry product for radiation therapy

Diepenbeek, Belgium - January 28, 2021 - DoseVue NV, a privately held medical device company developing in-vivo dosimetry solutions for radiation therapy, today announces the CE marking of its first product: the DoseWire™ Series 200.

eTheRNA and China Grand Pharma enter a strategic collaboration in the Greater China Region focussed on eTheRNA’s proprietary mRNA development products and manufacturing capabilities

Niel, Belgium, 1 December 2020 - eTheRNA immunotherapies NV (“eTheRNA”) announced it has entered into a strategic cooperation and product license agreement with China Grand Pharmaceutical & Healthcare Holdings Ltd (“China Grand Pharma”) to establish a new joint venture company, Nanjing AuroRNA Biotech Co., Ltd. (“AuroRNA Biotech”) in Mainland China to deploy eTheRNA’s proprietary mRNA technology for pharmaceutical research and development and production in the Greater China Region.

Newton Biocapital I invests in Perseus Proteomics Inc. in Japan to develop therapeutic antibodies for the treatment of blood cancers

Brussels, Belgium / Tokyo, Japan – 1 December 2020 – Newton Biocapital I (“Newton”), a life sciences investment fund active in Europe and Japan and focused on the treatment and prevention of chronic diseases, has announced its third investment in Japan. Newton invested EUR 1.2 million (JPY 148 million) in Perseus Proteomics Inc. as part of a total round of EUR 8.1 million. With this investment, Perseus Proteomics will continue its research and development of PPMX-T003 - a key growth driver antibody - and other antibodies in the pipeline.

V-Bio Ventures invests in new start-up Animab in a EUR 3.4 million Seed Financing to improve health and performance of livestock animals

Gent, Belgium, 27 October 2020 – Today V-Bio Ventures announces its investment in Animab, a new venture spin-off from VIB, in a EUR 3.4 million Seed financing round. The company develops monoclonal antibodies for oral administration to ensure intestinal health of livestock. The initial focus is on improving the resilience of piglets during the fragile post-weaning period. The start-up will use the seed capital to develop its first oral antibody product for protection against ETEC and initiate a product portfolio for the livestock industry.

Montis Biosciences appoints Karen Zinkewich-Péotti as Chief Executive Officer

Leuven, Belgium, 29 September 2020 - Montis Biosciences, a discovery stage biotech company focused on novel immuno-oncology therapeutics targeting the interactions between perivascular macrophages and the tumor vasculature, has named Karen Zinkewich-Péotti, Ph.D., as its Chief Executive Officer.  Dr. Zinkewich-Péotti brings strong R&D leadership experience from both international biopharmaceutical companies and smaller biotech.  Over the course of her career she has developed extensive expertise in different therapeutic modalities, including antibodies, antibody-drug conjugates and small molecules.

Biodol Therapeutics receives EUR 4.5 million to progress its novel pain medication in a Series A led by V-Bio Ventures

V-Bio Ventures, a leading Belgian life sciences VC, invests in Biodol Therapeutics, a French biotech specialized in next-generation chronic pain treatments. Biodol Therapeutics receives EUR 4.5 million to develop novel FLT3 inhibitors for the treatment of chronic and neuropathic pain, aiming to reach the clinic by early 2023.

Newton Biocapital I invests in J-Pharma Co., Ltd. in Japan focusing on drug development targeting L-type Amino Acid Transporter 1 (LAT1) for cancer and autoimmune diseases

Brussels, Belgium / Tokyo, Japan – 27 August 2020 – Newton Biocapital I (“Newton”), an investment company in life sciences, focusing on the treatment and prevention of chronic diseases, with activities in Europe and Japan, has announced its second investment in Japan. Newton invested JPY 480 million (EUR 4 million) – split in two tranches - in J-Pharma Co., Ltd. (“J-Pharma”) as part of a total Series D round of JPY 1.746 billion (EUR 14.55 million) as of July 30, 2020. Newton’s investment in J-Pharma was also its first new investment after it has closed its fund raising at EUR 114 million.

Lewis Cantley awarded Dr. Paul Janssen Award for Biomedical Research 2020

Johnson & Johnson Celebrates Role of Scientists In Society with 2020 Dr. Paul Janssen Award for Biomedical Research, Part of the Champions of Science® Initiative - Lewis Cantley, Ph.D. Named 2020 Award Winner for the Discovery of PI3K Enzyme and its Role in Wide Range of Diseases from Diabetes to Cancer

V-Bio invests into ExeVir Bio to accelerate development of new treatment conferring broad protection against Covid-19

Ghent, Belgium, 28 July 2020 – Today V-Bio Ventures announces its investment in a EUR 23 million Series A financing into ExeVir Bio. The round was led by Fund+, with the participation, next to V-Bio Ventures, of VIB, UCB Ventures, SFPI-FPIM, and several Belgian family offices. ExeVir Bio has been established by Belgian partners combining world class science, antibody engineering, manufacturing, blue-chip venture capital investment and Flemish Government financing, which have joined forces in a unique collaboration to boost the development of new therapies to combat Covid-19.

Anacura, a Belgian biotech company, sells stem cell business to Boehringer Ingelheim

Ghent, Belgium, 27 July 2020 – GST, the stem cell specialist for horses and pets within the Anacura Group, has been acquired by Boehringer Ingelheim. The acquisition follows two years of successful cooperation. Research and production will continue in Anacura’s labs, close to Ghent, Belgium. The current management and staff will play a crucial role in the implementation and further development of stem cell technology within Boehringer Ingelheim.

Max Planck researchers feed Proteome AI with PharmaFluidics technology

Micro-chip based µPAC™ LC columns - key component in NATURE study doubling the universe of known proteins across all kingdoms of life

PharmaFluidics awarded VLAIO research grant

Funding will support product range extension of micro-chip based µPAC™ nano, capillary and microflow LC columns, and accelerated development of manufacturing process know-how.

BioVox: the global network for Belgian life sciences turns five and launches a new website!

Ghent (Belgium), 7 May 2020 - For the past five years, BioVox has provided a growing international community of readers with insights into the Belgian life sciences ecosystem. Our free monthly newsletter features exclusive content on the latest breakthroughs and industry developments. After half a decade of success, BioVox has now launched a fresh new website featuring Onno Van De Stolpe sharing his insights on the Belgian life sciences ecosystem.

Biogazelle initiates large-scale testing of COVID-19 in Belgium

Ghent, Belgium, April 2, 2020 - Biogazelle NV, a CRO specialized in RNA analytics, has announced the initiation of large-scale testing of patient samples for SARS-CoV-2. Biogazelle is providing one of the multiple testing sites in a government-led consortium of pharma, biotech, IT and academia, alongside Janssen Pharmaceutica (J&J), GSK, UCB, UgenTec, MIPS and ThermoFisher.